Dermata Therapeutics -CW26DRMAWPreferred / convertible
13F holders, Q2 2024 (June 30)4holders −1
0new positions
1sold out
$0.62avg. 13F price*
At the end of Q2 2024, 4 institutions reported holding Dermata Therapeutics -CW26 (DRMAW) in their 13F filings, down 1 from Q1 2024. 0 opened new positions and 1 sold out. The largest holders were Boothbay Fund Management, LLC ($29K), Warberg Asset Management LLC ($420) and UBS Group AG ($71).
- Company
- Dermata Therapeutics -CW26
- CUSIP
- 249845116
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $193 |
All 13F filers, Q1 2024 → Q2 2024: 3,657 shares bought and 20,312 shares sold, net −16,655 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Boothbay Fund Management, LLC | — | No change | 12,000 | $29K |
| Warberg Asset Management LLC | — | No change | 30,000 | $420 |
| UBS Group AG | — | Add +239.5% | 5,042 | $71 |
| Bank of America Corp. | — | Add +100.0% | 200 | $3 |
"% of holder's portfolio" is DRMAW's weight in each manager's 13F, not the share of Dermata Therapeutics -CW26 the manager owns.